Rubraca is the first PARP inhibitor approved for prostate cancer.
News & Analysis: Clovis Oncology
Clovis Oncology's stock reversed course last month.
Despite a busy few months with emergency use authorizations due to coronavirus, the Food and Drug Administration is expected to approve several new drugs in May.
CLVS earnings call for the period ending March 31, 2020.
Strong clinical trial results from AstraZeneca and Merck just made it harder for Clovis Oncology to reach profitability.
Investors piled into cancer stocks. Here's why.
The biotech is getting special attention from the moody market today. Here's why.
The cancer-drug maker has a novel medicine that may provide growth opportunities in other areas of cancer.
Sales of cancer drug Rubraca were higher than expected -- but so were the drugmaker's spending levels.
CLVS earnings call for the period ending December 31, 2019.